Thursday, November 12, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 26, 2026

Ibotta outlines Q1 2026 revenue guidance of $78M-$82M with LiveLift driving transformation

View original at seekingalpha.com
Ibotta outlines Q1 2026 revenue guidance of $78M-$82M with LiveLift driving transformation Earnings Call Insights: Ibotta, Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Q4 revenue and adjusted EBITDA were 7% and 31% above the midpoint of Q3 guidance respectively

    80% confidence
  • Companies added additional budget to same brands and added additional brands into the program

    80% confidence
  • Low single-digit sequential revenue growth expected in Q2 versus Q1, and slight year-over-year revenue growth expected in Q3

    80% confidence
  • Third-party redeemers grew by almost 3.5 million in Q4, with about one-third from existing publishers

    80% confidence
  • Q1 2026 revenue expected in range of $78 million to $82 million, representing 5% year-over-year decline at midpoint

    80% confidence
  • LiveLift is the most sophisticated capability and represents where the industry is heading

    80% confidence
  • Third-party redeemer growth attributed to new publisher partnerships and innovations in in-store and online awareness

    80% confidence
  • Clients can purchase sales lift studies just as they would for other forms of digital media through partnerships with Circana and ABCS Insights

    80% confidence
  • There's real emphasis on value among clients and Ibotta is well positioned in terms of the macro environment

    80% confidence
  • Q1 2026 adjusted EBITDA expected in range of $6 million to $8 million, representing about 9% adjusted EBITDA margin at midpoint

    80% confidence
  • Stock-based compensation expense expected to be approximately $10 million higher than 2025

    80% confidence
  • Broad-based sequential progress in year-over-year redemption revenue trends throughout Q4, with LiveLift revenue better than projected and SNAP program contributing incremental revenue

    80% confidence
  • LiveLift is a TAM expander with ability to provide ongoing, actionable metrics

    80% confidence
  • Q4 revenue and adjusted EBITDA are both above the top end of the guidance range, representing an improvement in year-over-year revenue trends compared to Q3

    80% confidence
  • Outperformance attributed to improved execution, core product strengthening, and expansion of LiveLift

    80% confidence
  • LiveLift allows clients to see projected incremental sales and cost per incremental dollar at various intervals during campaigns, enabling better optimization

    80% confidence
  • Average campaign size in LiveLift from companies piloting it is substantially larger than average campaign size in core Ibotta offering from same companies

    80% confidence
  • More offers, better quality offers, and longer duration on network drive more redemptions per redeemer

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com
Ibotta outlines Q1 2026 revenue guidance of $78M-$82M with LiveLift driving transformation — Source | Via News | Via News